Biocon Sdn Bhd enters Malaysia Book of Records
The 562,000 sq ft facility has been recognised as the first and largest integrated insulin manufacturer in Malaysia by MBR
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Biocon Biologics
India’s medicine watchdog under the scanner once again
Hopefully, this case will initiate as deep a clean up and introspection as the 2012 PCC report
Biocon Biologics denies bribery allegations
A statement from the company claimed that besides its employees, all its consultants, suppliers and partners are also bound by a…
Biocon Biologics and Viatris launch Abevmy in Canada
Abevmy, co-developed by the two companies, is a biosimilar to Roche’s Avastin (Bevacizumab), and has been approved by Health…
CCI approves Serum Institute Life Sciences-Biocon Biologics deal
Once the deal is complete, Serum Institute Life Sciences will have about 15 per cent stake in Biocon Biologics, according to the…
Biocon Q4FY22 revenue at Rs 2,476 crores, up 21 per cent
FY22 revenue at Rs 8,397 crores, up 14 per cent; core EBITDA up 18 per cent at Rs 2,669 crores; PBT (before Exceptional Item) at…
MoH, Malaysia, awards three-year contract to Biocon Biologics’s Insugen
Biocon Biologics’ Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices…
Biocon Biologics’ partner receives positive EU CHMP opinion for biosimilar human insulin for IV…
Celerity Pharma uses Biocon Biologics’ insulin drug substance to develop the product
Kiran Mazumdar-Shaw Elected as Fellow of Royal Society of Edinburgh
Shaw is among the 80 luminaries to be appointed to the RSE’s Fellowship this year
Biocon Biologics to acquire Viatris’ biosimilars assets for up to $3.335 billion
Viatris to provide commercial and other transition services for an expected period of two years to ensure continuity of customer…